Schafer Rachel M, Giancotti Luigino A, Chrivia John C, Li Ying, Mufti Fatma, Kufer Thomas A, Zhang Jinsong, Doyle Timothy M, Salvemini Daniela
Department of Pharmacology and Physiology, School of Medicine, Saint Louis University, St. Louis, MO, United States.
Institute for Translational Neuroscience, Saint Louis University, St. Louis, MO, United States.
Pain. 2025 Apr 1;166(4):902-915. doi: 10.1097/j.pain.0000000000003418. Epub 2024 Oct 1.
Neuropathic pain is a debilitating chronic condition that remains difficult to treat. More efficacious and safer therapeutics are needed. A potential target for therapeutic intervention recently identified by our group is the G-protein coupled receptor 160 (GPR160) and the cocaine- and amphetamine-regulated transcript peptide (CARTp) as a ligand for GPR160. Intrathecal administration of CARTp in rodents causes GPR160-dependent behavioral hypersensitivities. However, the molecular and biochemical mechanisms underpinning GPR160/CARTp-induced behavioral hypersensitivities in the spinal cord remain poorly understood. Therefore, we performed an unbiased RNA transcriptomics screen of dorsal horn spinal cord (DH-SC) tissues harvested at the time of peak CARTp-induced hypersensitivities and identified nucleotide-binding oligomerization domain-containing protein 2 ( Nod2 ) as a gene that is significantly upregulated. Nucleotide-binding oligomerization domain-containing protein 2 is a cytosolic pattern-recognition receptor involved in activating the immune system in response to bacterial pathogens. While NOD2 is well studied under pathogenic conditions, the role of NOD2-mediated responses in nonpathogenic settings is still not well characterized. Genetic and pharmacological approaches reveal that CARTp-induced behavioral hypersensitivities are driven by NOD2, with co-immunoprecipitation studies indicating an interaction between GPR160 and NOD2. Cocaine- and amphetamine-regulated transcript peptide-induced behavioral hypersensitivities are independent of receptor-interacting protein kinase 2 (RIPK2), a common adaptor protein to NOD2. Immunofluorescence studies found NOD2 co-expressed with endothelial cells rather than glial cells, implicating potential roles for CARTp/NOD2 signaling in these cells. While these findings are based only on studies with male mice, our results identify a novel pathway by which CARTp causes behavioral hypersensitivities in the DH-SC through NOD2 and highlights the importance of NOD2-mediated responses in nonpathogenic settings.
神经性疼痛是一种使人衰弱的慢性疾病,治疗起来仍然很困难。因此需要更有效、更安全的治疗方法。我们团队最近确定的一个潜在治疗干预靶点是G蛋白偶联受体160(GPR160)以及作为GPR160配体的可卡因和苯丙胺调节转录肽(CARTp)。在啮齿动物中鞘内注射CARTp会导致依赖GPR160的行为超敏反应。然而,GPR160/CARTp诱导脊髓行为超敏反应的分子和生化机制仍知之甚少。因此,我们对在CARTp诱导超敏反应高峰期采集的背角脊髓(DH-SC)组织进行了无偏向性RNA转录组学筛选,并确定含核苷酸结合寡聚化结构域蛋白2(Nod2)为显著上调的基因。含核苷酸结合寡聚化结构域蛋白2是一种胞质模式识别受体,参与激活免疫系统以应对细菌病原体。虽然NOD2在致病条件下已得到充分研究,但其在非致病环境中介导的反应作用仍未得到很好的表征。遗传和药理学方法表明,CARTp诱导的行为超敏反应由NOD2驱动,免疫共沉淀研究表明GPR160与NOD2之间存在相互作用。可卡因和苯丙胺调节转录肽诱导的行为超敏反应独立于受体相互作用蛋白激酶2(RIPK2),RIPK2是NOD2常见的衔接蛋白。免疫荧光研究发现NOD2与内皮细胞而非神经胶质细胞共表达,这暗示了CARTp/NOD2信号在这些细胞中的潜在作用。虽然这些发现仅基于对雄性小鼠的研究,但我们的结果确定了一条新的途径,通过该途径CARTp通过NOD2在DH-SC中引起行为超敏反应,并强调了NOD介导的反应在非致病环境中的重要性。